The clinical significance of soluble E-cadherin in nonsmall cell lung cancer
Aim: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed patients with non small cell lung cancer (N...
Gespeichert in:
| Datum: | 2006 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2006
|
| Schriftenreihe: | Experimental Oncology |
| Schlagworte: | |
| Online Zugang: | http://dspace.nbuv.gov.ua/handle/123456789/137548 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Zitieren: | The clinical significance of soluble E-cadherin in nonsmall cell lung cancer / K. Charalabopoulos, A. Gogali, Y. Dalavaga, G. Daskalopoulos, M. Vassiliou, G. Bablekos, A. Karakosta, S. Constantopoulos // Experimental Oncology. — 2006. — Т. 28, № 1. — С. 83-85. — Бібліогр.: 24 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-137548 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1375482018-06-18T03:02:57Z The clinical significance of soluble E-cadherin in nonsmall cell lung cancer Charalabopoulos, K. Gogali, A. Dalavaga, Y. Daskalopoulos, G. Vassiliou, M. Bablekos, G. Karakosta, A. Constantopoulos, S. Short communications Aim: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed patients with non small cell lung cancer (NSCLC) was investigated. Material and Methods: An enzyme linked immunospecific assay (ELISA) to determine the circulating levels of sE-cad in 20 newly diagnosed patients with NSCLC as well as in 29 healthy volunteers (control group) was used. Results: NSCLC patients exerted increased circulating levels of sE-cad compared with individuals of the control group (p < 0.001). An association was also detected between serum sE-cad levels and the development of distant metastases. On the contrary, no statistically significant correlation could be established with histological type, gender and smoking habits. Patients with increased sE-cad levels at diagnosis had worser outcome, although multivariate analysis failed to demonstrate that sE-cad levels represent an independent prognostic factor of survival. Conclusion: Our data suggest that E-cad plays a role in the pathogenesis of NSCLC. sE-cad levels may be further studied as a potential prognostic biomarker. Цель: нарушения экспрессии трансмембранной молекулы адгезии эпителия Е-кадерина (Е-cad) ассоциированы со злокачеcтвенными новообразованиями у человека. Цель исследования — оценить клиническое значение содержания секретируемого Е-кадерина (sE-cad) в сыворотке крови больных с диагнозом немелкоклеточного рака легкого (НМКРЛ). Материалы и методы: для определения уровня циркулирующего sE-cad в сыворотке крови 20 больных с НМКРЛ и 29 здоровых доноров применили метод ELISA. Результаты: у больных с НМКРЛ выявлено значительное повышение содержания циркулирующего sE-cad в сыворотке крови по сравнению с таковым в контрольной группе (p < 0,001). Установлена связь между уровнем sE-cad в сыворотке крови и появлением периферических метастазов. Не выявлено статистически достоверной корреляции между гистологическим типом опухоли, полом больного и курением. У пациентов с повышенным содержанием sE-cad наблюдалась тенеденция к худшему исходу заболевания, хотя результаты статистического анализа не подтвердили прогностического значения sE-cad. Выводы: полученные данные позволили предположить, что E-cad участвует в патогенезе НМКРЛ. Оценка содержания sE-cad в качестве прогностического биомаркера нуждается в дальнейшем исследовании. 2006 Article The clinical significance of soluble E-cadherin in nonsmall cell lung cancer / K. Charalabopoulos, A. Gogali, Y. Dalavaga, G. Daskalopoulos, M. Vassiliou, G. Bablekos, A. Karakosta, S. Constantopoulos // Experimental Oncology. — 2006. — Т. 28, № 1. — С. 83-85. — Бібліогр.: 24 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/137548 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Short communications Short communications |
| spellingShingle |
Short communications Short communications Charalabopoulos, K. Gogali, A. Dalavaga, Y. Daskalopoulos, G. Vassiliou, M. Bablekos, G. Karakosta, A. Constantopoulos, S. The clinical significance of soluble E-cadherin in nonsmall cell lung cancer Experimental Oncology |
| description |
Aim: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed patients with non small cell lung cancer (NSCLC) was investigated. Material and Methods: An enzyme linked immunospecific assay (ELISA) to determine the circulating levels of sE-cad in 20 newly diagnosed patients with NSCLC as well as in 29 healthy volunteers (control group) was used. Results: NSCLC patients exerted increased circulating levels of sE-cad compared with individuals of the control group (p < 0.001). An association was also detected between serum sE-cad levels and the development of distant metastases. On the contrary, no statistically significant correlation could be established with histological type, gender and smoking habits. Patients with increased sE-cad levels at diagnosis had worser outcome, although multivariate analysis failed to demonstrate that sE-cad levels represent an independent prognostic factor of survival. Conclusion: Our data suggest that E-cad plays a role in the pathogenesis of NSCLC. sE-cad levels may be further studied as a potential prognostic biomarker. |
| format |
Article |
| author |
Charalabopoulos, K. Gogali, A. Dalavaga, Y. Daskalopoulos, G. Vassiliou, M. Bablekos, G. Karakosta, A. Constantopoulos, S. |
| author_facet |
Charalabopoulos, K. Gogali, A. Dalavaga, Y. Daskalopoulos, G. Vassiliou, M. Bablekos, G. Karakosta, A. Constantopoulos, S. |
| author_sort |
Charalabopoulos, K. |
| title |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer |
| title_short |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer |
| title_full |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer |
| title_fullStr |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer |
| title_full_unstemmed |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer |
| title_sort |
clinical significance of soluble e-cadherin in nonsmall cell lung cancer |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2006 |
| topic_facet |
Short communications |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/137548 |
| citation_txt |
The clinical significance of soluble E-cadherin in nonsmall cell lung cancer /
K. Charalabopoulos, A. Gogali, Y. Dalavaga, G. Daskalopoulos, M. Vassiliou, G. Bablekos,
A. Karakosta, S. Constantopoulos // Experimental Oncology. — 2006. — Т. 28, № 1. — С. 83-85. — Бібліогр.: 24 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT charalabopoulosk theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT gogalia theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT dalavagay theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT daskalopoulosg theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT vassilioum theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT bablekosg theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT karakostaa theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT constantopouloss theclinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT charalabopoulosk clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT gogalia clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT dalavagay clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT daskalopoulosg clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT vassilioum clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT bablekosg clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT karakostaa clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer AT constantopouloss clinicalsignificanceofsolubleecadherininnonsmallcelllungcancer |
| first_indexed |
2025-07-10T02:34:46Z |
| last_indexed |
2025-07-10T02:34:46Z |
| _version_ |
1837225622221357056 |
| fulltext |
Experimental Oncology 28, 83–85, 2006 (March) 83
Lung cancer is the leading cause of cancer death in
both women and men in the USA, Canada and China.
In Europe and Australia it is the number one cause of
death from cancer in men and the third cause — in
women [1]. Cigarette smoke is by far the most signifi-
cant factor in the causation of lung cancer. Approxi-
mately 85% of lung cancer cases occur in smokers or
former smokers [2].
Epithelial tumors, which present the majority of lung
tumors, are classified primarily into two subgroups:
small cell lung cancer (SCLC) and nonsmall cell lung
cancer (NSCLC). NSCLC is composed of squamous
cell, adeno-, large cell and adeno-squamous carci-
noma. A subtype of adenocarcinoma is the bronchio-
alveolar cell carcinoma. As the 5-year survival for lung
cancer is currently 13% mainly due to metastasis the
devastation caused by this single cancer type de-
serves special attention.
Cell adhesion is a key process because it is di-
rectly related to the differentiation, architecture and
normal tissue development. It has been postulated
that changes in cell-cell and cell-matrix interactions
are responsible for the cancer cells transgression
to normal tissue boundaries and their dispersion to
distant sites [3–5]. The interactions among cells or
among cells and substrate are mediated by molecules
named adhesion molecules [6–8].
Cadherins represent the most important super-
family of adhesion molecules. In their presence, even
the absence of the rest of the adhesion molecules does
not influence the whole adhesion process.
The epithelial transmembrane molecule E-cadherin
(E-cad) is the prime mediator of epithelial cell-cell
adhesion acting in a homotypic fashion. It participates
in the development and architecture maintenance of
epithelial tissues as well as in the signalling process.
Cadherin superfamily consists of more than 40 mem-
bers, which share common characteristics. Among
cadherins E-cadherin is the most important mol-
ecule. E-cadherin (epithelial cadherin) is expressed
in epithelial tissues being involved in formation and
maintenance of the histoarchitecture. Other cadherins
are N–cadherin (neural cadherin) which is found at the
neural and muscular tissues, P-cadherin (placental
cadherin) found in embryonic tissues and placenta,
R-cadherin (retinal cadherin), VE-cadherin (vascular
endothelial cadherin) etc [9, 10].
Loss of the function or/and the expression of any of
the elements of the E-cadherin/catenins complex im-
pair cell adhesiveness resulting to a loss of the normal
tissue architecture [11]. Reduced/absent expression
of E-cadherin has been found in a variety of human
carcinomas including gastric, head and neck, blad-
der, prostate, colorectal and breast cancer [12–16].
Relatively recent immunohistochemical studies have
clearly shown that downregulation of E-cadherin is also
associated with lung cancer while prospective studies
are also in process to investigate the role of adhesion
molecules in various lung diseases [17]. Moreover,
abnormal expression of E-cad has been detected in
premalignant lesions such as Barrett’s oesophagus
[18], chronic active type B gastritis [19] and cervical
intraepithelial neoplasia (CIN) [20].
tHE CLINICAL SIGNIFICANCE OF SOLUBLE E-CADHERIN
IN NONSMALL CELL LUNG CANCER
K. Charalabopoulos1,*, A. Gogali1,2, Y. Dalavaga2, G. Daskalopoulos2,
Μ. Vassiliou2, G. Bablekos1, A. Karakosta1, S. Constantopoulos2
1Department of Physiology, Clinical Unit, Ioannina University Medical Faculty, Ioannina, Greece
2Department of Pneumonology, Ioannina University Medical Faculty, Ioannina, Greece
Aim: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many
human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed
patients with non small cell lung cancer (NSCLC) was investigated. Material and Methods: An enzyme linked immunospecific assay
(ELISA) to determine the circulating levels of sE-cad in 20 newly diagnosed patients with NSCLC as well as in 29 healthy volun-
teers (control group) was used. Results: NSCLC patients exerted increased circulating levels of sE-cad compared with individuals
of the control group (p < 0.001). An association was also detected between serum sE-cad levels and the development of distant
metastases. On the contrary, no statistically significant correlation could be established with histological type, gender and smoking
habits. Patients with increased sE-cad levels at diagnosis had worser outcome, although multivariate analysis failed to demonstrate
that sE-cad levels represent an independent prognostic factor of survival. Conclusion: Our data suggest that E-cad plays a role in
the pathogenesis of NSCLC. sE-cad levels may be further studied as a potential prognostic biomarker.
Key Words: E-cadherin, transmembrane adhesion molecule, malignancy, non small cell lung cancer, prognostic biomarker.
Exp Oncol 2006
28, 1, 83–85
Received: January 26, 2006.
*Correspondence: Fax: +3 2651 0 97850
E-mail: kcharala@cc.uoi.gr
Abbreviations used: CAM — cell-cell adhesion molecule;
CEA —carcinoembryonic antigen; CIN — cervical intraepithelial
neoplasia; E-cad — epithelial cadherin; N-cad — neural cadherin;
NSCLC — non small cell lung cancer; P-cad — placental cadherin;
SAM — substrate adhesion molecule; SCLC — small cell lung
cancer; sE-cad — soluble epithelial cadherin; VE-cad — vascular
endothelial cadherin.
84 Experimental Oncology 28, 83–85, 2006 (March)
In the present study an attempt to establish the role
of the E-cad, in particular the one of its soluble frag-
ment, in cases of NSCLC is made. SE-cad is a soluble
80 kDa fragment of E-cad that derives from shedding
of this molecule.
Twenty patients (17 males, 3 females, mean
age — 61 years) with recently diagnosed NSCLC were
enrolled in the present study (the histological type —
adenocarcinoma (n = 9), squamous cell carcinoma
(n = 8), large cell carcinoma (n = 3)). 19 patients were
smokers while 1 was a non-smoker (Table). A group of
29 healthy volunteers was used as control group.
Table. Clinicopathological data of patients with NSCLC and the
sE-cadherin level in the blood serum
Histological type Number of patients
Αdenocarcinoma (AC) 9 (46%)
Squamous cell carcinoma (SCC) 8 (40%)
Large cell carcinoma (LCC) 3 (15%)
Number Age Gender
Histo-
logical
type
Smoking
sΕ-cad-
herin
(ng/ml)
Distant
meta-
stases
1 52 M AC + 4382 +
2 56 M AC + 3894 +
3 79 M AC + 4565 +
4 57 M AC + 2186
5 62 M AC + 4877 +
6 54 M AC + 2386
7 49 M AC + 2650
8 66 F AC + 4667 +
9 51 F AC - 2376
10 82 M SCC + 2586
11 82 M SCC + 4580 +
12 75 M SCC + 2872
13 74 F SCC + 2858
14 48 M SCC + 4750 +
15 60 M SCC + 1942
16 56 M SCC + 4662 +
17 48 M SCC + 2287
18 57 M LCC + 3068 +
19 64 M LCC + 4777 +
20 72 M LCC + 2735
Abbreviations: M — male, F — female;
Mean value of sΕ-cad: 3455 ng/ml;
Range: 1942–4877 ng/ml.
At the time of diagnosis blood samples were taken,
centrifuged, routinely processed and kept at −70 oC
until measurement. Measurement of sE-cad in serum
of patients and healthy individuals was achieved with
an ELISA method using commercial kit with specific
monoclonal antibodies against E-cad (R&D systems,
UK). Results were statistically analyzed using Stu-
dent’s t-test. Values of p < 0.001 were considered as
statistically significant.
The major clinicopathological characteristics of the
20 patients are presented in the Table. Serum levels of
E-cad were increased in cases of NCSLC compared to
these in control group (p < 0.001). In particular, in the
control group a mean value of sE-cad was 1015 ng/ml,
whilst in the group of patients — 3455 ng/ml.
On the other hand, no statistically significant dif-
fer- ence could be established between the levels of
sE cad and the histological type, sex and smoking habit
(control group, only one non-smoker participated in
the patients’ group). On the contrary, increased serum
levels of sE-cad correlated with the development of
distant metastasis (p < 0.001); patients with general-
ized disease presented marked increase of sE-cad
levels. Furthermore, the levels of sE-cad do not cor-
relate with the histological type of tumor. Thus, E-cad
can not be used as a marker for differential diagnosis
of NSCLC subtypes. Finally, a statistically significant
difference has not been found between men and
women and/or smokers and non-smokers. Of course,
the number of the patients studied herein is limited and
we have to take under consideration the possibility of
a not fully objective view due to the small number of
patients. Patients with increased levels of sE-cad at the
time of the diagnosis had worsier prognosis, although
multivariate analysis failed to prove that E-cad levels
are an independent prognostic indicator of survival.
According to a number of studies, the immuno-
chemical analysis of E-cad complex in lung cancer
patients showed also a downregulation of the E-cad
expression. Particularly, in NSCLC cases low levels of
E-cadherin expression in abnormal patterns — apart
from its membranous expression seen normally — have
been found in all histological types and especially in
poorly and moderately differentiated carcinomas [21,
22]. In addition, E-cad expression has been shown to
be reversely correlated with that of epidermal growth
factor receptor that is overexpressed in the majority
of lung cancers and correlates with poor prognosis
[23]. At the present study, it has been demonstrated
that the levels of circulating sE-cad are significantly
increased in cases of NSCLC of all histological types
when compared to healthy individuals. In particular,
the degree of sE-cad increase correlated with the
existence of distant metastases. Similar results with
increased sE-cad levels have been reported in prostate
cancer cases [24].
The question is what is the specific role that
soluble E-cad plays in the whole process, what is its
importance and how this can prove useful in cancer
procedure. Probably, increased levels in serum reflect
serious dysfunction of cellular E-cad since they are
much higher that in healthy individuals. Changes in the
expression levels of E-cad affect the adhesive ability
of the tissues and in this way low expression results
in weakening of the role of E-cad as an inhibitor of
cancer invasion along with the capability of migration
of cancer cells to distant organs.
In conclusion, further studies including a larger
number of patients are needed in order to fully elu-
cidate the role of sE-cad and to establish E-cadherin
as a useful biomarker in diagnosis and prognosis of
NSCLC. A very interesting view of this issue is being
given by current studies in which the possibility of us-
ing sE-cad as a marker of response to chemotherapy
is investigated.
REFERENCES
1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer
statistics 1998. CA Cancer J Clin 1998; 48: 6–29.
2. American Thoracic Society Statement: cigarette smoking
and health. Am J Respir Crit Care Med 1996; 153: 861–5.
3. Charalabopoulos K, Binolis J, Karkabounas S. Adhesion
molecules in carcinogenesis. Exp Oncol 2002; 24: 249–57.
4. Charalabopoulos K, Pignatelli M. Adhesion molecules
and cancer. Arch Hell Med 2001; 18: 16–9.
Experimental Oncology 28, 83–85, 2006 (March) 85
5. Charalabopoulos K, Papalimneou V, Charalabopou-
los A. Adhesion molecules in lung cancer. Exp Oncol 2003;
25: 16–21.
6. Gogali A, Charalabopoulos K, Constantopoulos S.
Integrins receptors in primary lung cancer Exp Oncol 2004;
26: 106–10.
7. Eideman GM, Crossin KL. Cell adhesion molecules:
implication for a molecular histology. Ann Rev Biochem
1991; 60: 155–90.
8. Takeichi M. Cadherin сell adhesion receptors as a mor-
phogenetic regulator. Science 1991; 251: 1451–5.
9. Takeichi M. Cadherins in cancer: implications for inva-
sion and metastasis. Curr Opin Cell Biol 1993; 5: 806–911.
10. Kemler R. From cadherins to catenins; cytoplasmic
protein interactions and regulation of cell adhesion. Trends
Genet 1993; 9: 317–21.
11. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM,
Schildberg FW, Birchmeier W, Funke I. E-cadherin expression
in primary and metastatic gastric cancer: down-regulation
correlates with cellular dedifferentiation and glandular disin-
tegration. Cancer Res 1993; 53: 1690–5.
12. Schipper JH, Frixen UH, Behrens J, Unger A,
Jahnke K, Birchmeier W. E-cadherin expression in squamous
cell carcinomas of head and neck: inverse correlation with
tumor dedifferentiation and lymph node metastasis. Cancer
Res 1991; 51: 6328–37.
13. Charalabopoulos K, Tsambalas S, Syrigos K, Giannako-
poulos X, Kalfakakou V, Kiortsis D, Alamanos J, Charalabopou-
los A, Evangelou A. Correlation of E-cadherin expression with
clinicopathological data in patients suffering from transitional
cell carcinoma of the bladder. Exp Oncol 2003; 25: 180–5.
14. Umbas R, Schalken JA, Aalders TW, Carter BS,
Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB.
Expression of the cellular adhesion molecule E-cadherin is
reduced or absent in high-grade prostate cancer. Cancer Res
1992; 52: 5104–9.
15. Dorudi S, Sheffield JP, Poulsom R, Northover JM,
Hart IR. E-cadherin expression in colorectal cancer. An
immunocytochemical and in situ hybridization study. Am J
Pathol 1993; 142: 981–6.
16. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H,
Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M.
Expression of E-cadherin cell adhesion molecules in human
breast cancer tissues and its relationship to metastasis. Cancer
Res 1993; 53: 1696–701.
17. Charalabopoulos K, Karachalios G. Adhesion molecules
and lung disease. Pneumon Med J 2000; 13: 50–6.
18. Syrigos KN, Karagiannakis AJ, Charalabopoulos K,
Katirtzoglou N, Pignatelli M. Abnormal expression of E-cad-
herin in dysplastic Barrett’s oesophagus. Ann Gastroenterol
2000; 13: 168.
19. Charalabopoulos K, Papalimneou V, Euangelou A, Kal-
fakakou V, Kiortsis D, Kolettas E, Alamanos J, Charalabopoulos A,
Agnantis NJ. Is the E-cadherin downregulation observed in
Helicobacter pylori infection associated with gastric cancer de-
velopment? An additional element in the disease jigsaw. Exp
Oncol 2003; 25: 270–3.
20. Vessey CJ, Wilding J, Folarin N, Hirano S, Takeichi M,
Soutter P, Stamp GW, Pignatelli M. Altered expression and
function of E-cadherin in cervical intraepithelial neoplasia and
invasive squamous cell carcinoma. J Pathol 1995; 176: 151–9.
21. Bohm M, Totzeck B, Birchmeier W, Wieland I. Differ-
ences of E-cadherin expression levels and patterns in primary
and metastatic human lung cancer. Clin Exp Metastasis 1994;
12: 55–62.
22. Toyoyama H, Nuruki K, Ogawa H, Yanagi M, Mat-
sumoto H, Nishijima H, Shimotakahara T, Aikou T, Ozawa M.
The reduced expression of E-cadherin, α-catenin and
γ-catenin but not β-catenin in human lung cancer. Oncol
Rep 1999; 6: 81–5.
23. Al Moustafa AE, Yansouni C, Alaoui-Jamali M,
O’Connor-McCourt M. Upregulation of E-cadherin by an
anti-epidermal growth factor receptor monoclonal antibody in
lung cancer cell lines. Clin Cancer Res 1999; 5: 681–6.
24. Ahmed MI, Abd-Elmotelib F, Farag RM, Ziada NA,
Khalifa A. Evaluation of some tissue and serum biomarkers
in prostatic carcinoma among Egyptian males. Clin Biochem
1999; 32: 439–45.
КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ОПРЕДЕЛЕНИЯ СЕКРЕтИРуЕмОгО
Е-КАДЕРИНА В СЫВОРОтКЕ КРОВИ бОЛьНЫх
НЕмЕЛКОКЛЕтОЧНЫм РАКОм ЛЕгКОгО
Цель: нарушения экспрессии трансмембранной молекулы адгезии эпителия Е-кадерина (Е-cad) ассоциированы со злокаче-
cтвенными новообразованиями у человека. Цель исследования — оценить клиническое значение содержания секретируемого
Е-кадерина (sE-cad) в сыворотке крови больных с диагнозом немелкоклеточного рака легкого (НМКРЛ). Материалы и
методы: для определения уровня циркулирующего sE-cad в сыворотке крови 20 больных с НМКРЛ и 29 здоровых доноров
применили метод ELISA. Результаты: у больных с НМКРЛ выявлено значительное повышение содержания циркули-
рующего sE-cad в сыворотке крови по сравнению с таковым в контрольной группе (p < 0,001). Установлена связь между
уровнем sE-cad в сыворотке крови и появлением периферических метастазов. Не выявлено статистически достоверной
корреляции между гистологическим типом опухоли, полом больного и курением. У пациентов с повышенным содержанием
sE-cad наблюдалась тенеденция к худшему исходу заболевания, хотя результаты статистического анализа не подтвердили
прогностического значения sE-cad. Выводы: полученные данные позволили предположить, что E-cad участвует в патогенезе
НМКРЛ. Оценка содержания sE-cad в качестве прогностического биомаркера нуждается в дальнейшем исследовании.
Ключевые слова: Е-кадерин, молекула трансмембранной адгезии, малигнизация, немелкоклеточный рак легкого, про-
гностический биомаркер.
Copyright © Experimental Oncology, 2006
|